This study will involve participating in one of two interventions to help adult patients who have had a stroke control their blood pressure: 1) an Intensive Clinic Management model (also called ICM), that includes clinic visits and health education versus 2) an Intensive Tailored Telehealth Management model (also called ITTM) that includes individualized care planning, health coaching, and referrals to needed community resources. Participation includes about 4 study visits over a period of 16 weeks, which will be performed during in-person clinic visits, through video call, or over the phone. Participants will be compensated for their time and participation in this research study.

We are studying whether visual field testing can be completed using a virtual reality headset with software designed and installed to cause a "blink to threat" response. A positive "blink to threat" response implies an intact visual field. Subject volunteers will have both in person "blink to threat" visual field testing and headset "blink to threat" visual field testing. We are testing the accuracy, timing, tolerability and satisfaction (of both examiner and patient) with the use of virtual reality visual field testing.

We propose to enroll 150 individuals with acute stroke admitted to MUSC over the next 12 months and randomize them into increased frequency and usual care PT treatment groups. This study will be designed as a randomized control trial. Patients who agree to participate, will be assigned (at random) to either a treatment group which will receive more frequent intensive therapy services or to the control group (treatment as usual) which will receive the standard amount of therapy services currently provided in the hospital setting (~3-5 times per week). By studying the balance, walking and success of patients in the treatment group compared with the standard of care group- we hope to better understand the effect of more frequent physical therapy services on a patient's independence post stroke.

ARCADIA is a multicenter, biomarker-driven, randomized, double-blind, active-control, phase 3 clinical trial of apixaban (Eliquis) versus aspirin in patients who have evidence of atrial cardiopathy and a recent stroke of unknown cause. 1100 subjects will be recruited over 6 years at 120 sites in the NINDS StrokeNet consortium. Subjects will be followed for a minimum of 1.5 years and a maximum of 7 years for the primary efficacy outcome of recurrent stroke and the primary safety outcomes of symptomatic intracranial hemorrhage and major hemorrhage other than intracranial hemorrhage.

CREST-2 is two parallel multi-center randomized, observer-blinded endpoint clinical trials. One trial will assess treatment differences between intensive medical management alone compared to carotid endarterectomy procedure plus intensive medical management. The parallel trial will assess treatment differences between intensive medical management alone compared to carotid artery stenting plus intensive medical management. Intensive medical management will involve control of blood pressure, LDL cholesterol, cigarette smoking, and other vascular risk factors.